<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02207491</url>
  </required_header>
  <id_info>
    <org_study_id>AR-13324-CS301</org_study_id>
    <nct_id>NCT02207491</nct_id>
  </id_info>
  <brief_title>Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <acronym>Rocket-1</acronym>
  <official_title>A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324
      Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic
      Solution, 0.5%
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>3 months</time_frame>
    <description>The primary efficacy outcome is mean IOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of Exposure</measure>
    <time_frame>3 months</time_frame>
    <description>Exposure to study medication in days for all treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol maleate Ophthalmic Solution 0.5% BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) &amp; evening (PM) in both eyes (OU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate Ophthalmic Solution 0.5% BID</intervention_name>
    <description>1 drop BID, AM/PM, OU</description>
    <arm_group_label>Timolol maleate Ophthalmic Solution 0.5% BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-13324 Ophthalmic Solution 0.02%</intervention_name>
    <description>1 drop once daily (QD), PM, OU</description>
    <arm_group_label>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</arm_group_label>
    <other_name>Netarsudil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 drop QD, AM, OU</description>
    <arm_group_label>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion criteria:

          1. 0-2 years of age and 18 years or greater.

          2. Diagnosis of open angle glaucoma or ocular hypertension

          3. Unmedicated (post-washout) IOP (Intraocular Pressure) &gt;20 mm Hg and &lt; 27 mm Hg in the
             study eye at 2 qualification visits.

          4. Corrected visual acuity in each eye equivalent to 20/200.

          5. Able and willing to give signed informed consent (parent or guardian consent for
             pediatric patient) and follow study instructions.

        Subject exclusion criteria

        Ophthalmic:

          1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure,
             or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.

          2. Intraocular pressure ≥27 mm Hg (unmedicated) in both eyes (individuals who are
             excluded for this criterion are not allowed to attempt requalification), or use of
             more than two ocular hypotensive medications within 30 days of screening. Note: fixed
             dose combinations count as two medications.

          3. Known hypersensitivity to any component of the formulations to be used (benzalkonium
             chloride, etc.), to topical anesthetics or beta adrenoceptor antagonists.

          4. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye

          5. Refractive surgery in either eye.

          6. Ocular trauma in either eye within the six months prior to screening, or ocular
             surgery or non-refractive laser treatment within the three months prior to screening.

          7. Recent or current evidence of ocular infection or inflammation in either eye. Current
             evidence of clinically significant blepharitis, conjunctivitis, or a history of herpes
             simplex or zoster keratitis at screening in either eye.

          8. Ocular medication in either eye of any kind within 30 days of screening.

          9. Clinically significant ocular disease in either eye (e.g., corneal edema, uveitis,
             severe keratoconjunctivitis sicca) which might interfere with the study, including
             glaucomatous damage so severe that washout of ocular hypotensive medications for one
             month is not judged safe.

         10. Central corneal thickness in either eye greater than 600 µm at screening.

         11. Any abnormality in either eye preventing reliable applanation tonometry of either eye.

             Systemic:

         12. Clinically relevant abnormalities (as determined by the investigator) in laboratory
             tests at screening which may impact the study.

         13. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists (e.g.,
             chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood
             pressure or heart rate; second or third degree heart block or congestive heart
             failure; severe diabetes).

         14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia
             gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere
             with the study.

         15. Participation in any investigational study within 30 days prior to screening.

         16. Changes of systemic medication that could have an effect on intraocular pressure
             within 30 days prior to screening, or anticipated during the study.

         17. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control. An adult woman is considered
             to be of childbearing potential unless she is one year post-menopausal or three months
             post-surgical sterilization. All females of childbearing potential must have a
             negative urine pregnancy test result at the screening examination and must not intend
             to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Heah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aerie Pharmaceuticals</name>
      <address>
        <city>Bedminster</city>
        <state>New Jersey</state>
        <zip>07921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>July 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2014</study_first_posted>
  <results_first_submitted>January 17, 2018</results_first_submitted>
  <results_first_submitted_qc>April 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <disposition_first_submitted>July 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2015</disposition_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 35 clinical trial sites starting in June of 2014. The first participant was enrolled in July of 2014 and the last participant was enrolled in December of 2014.</recruitment_details>
      <pre_assignment_details>Prior to enrollment, adult participants were to have a Screening Visit and 2 Qualification Visits to allow for washout of ocular hypotensive medication if needed.
The Randomized Population includes all subjects who were randomized to treatment. Baseline variables and demographic characteristics were summarized for this population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</title>
          <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
        </group>
        <group group_id="P2">
          <title>Timolol Maleate Ophthalmic Solution 0.5% BID</title>
          <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Population</population>
      <group_list>
        <group group_id="B1">
          <title>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</title>
          <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
        </group>
        <group group_id="B2">
          <title>Timolol Maleate Ophthalmic Solution 0.5% BID</title>
          <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="411"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="11.65"/>
                    <measurement group_id="B2" value="64.2" spread="11.34"/>
                    <measurement group_id="B3" value="65.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>The primary efficacy outcome is mean IOP</description>
        <time_frame>3 months</time_frame>
        <population>Per-Protocol (PP) Population. The PP population includes subjects who did not have major protocol violations likely to seriously affect the primary outcome of the study. The PP population summarizes subjects as treated for purpose of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</title>
            <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate Ophthalmic Solution 0.5% BID</title>
            <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>The primary efficacy outcome is mean IOP</description>
          <population>Per-Protocol (PP) Population. The PP population includes subjects who did not have major protocol violations likely to seriously affect the primary outcome of the study. The PP population summarizes subjects as treated for purpose of analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0800 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" spread="1.756"/>
                    <measurement group_id="O2" value="23.37" spread="1.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1000 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.28" spread="2.128"/>
                    <measurement group_id="O2" value="21.92" spread="2.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1600 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.78" spread="2.385"/>
                    <measurement group_id="O2" value="21.45" spread="2.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 0800 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.68" spread="3.342"/>
                    <measurement group_id="O2" value="18.33" spread="2.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1000 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.29" spread="3.303"/>
                    <measurement group_id="O2" value="17.55" spread="2.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, 1600 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.24" spread="3.294"/>
                    <measurement group_id="O2" value="17.70" spread="2.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 0800 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.35" spread="3.629"/>
                    <measurement group_id="O2" value="18.24" spread="2.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 1000 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.14" spread="3.502"/>
                    <measurement group_id="O2" value="17.44" spread="2.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43, 1600 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86" spread="3.580"/>
                    <measurement group_id="O2" value="17.71" spread="2.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (month 3), 0800 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.81" spread="3.647"/>
                    <measurement group_id="O2" value="18.47" spread="2.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (month 3), 1000 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92" spread="3.702"/>
                    <measurement group_id="O2" value="17.96" spread="2.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (month 3), 1600 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.48" spread="3.595"/>
                    <measurement group_id="O2" value="17.74" spread="2.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming zero difference between AR-13324 and timolol, a 2-tailed alpha of 0.05 at each of 9 time points, a common SD of 3.0 mmHg, and a correlation between time points of 0.60 or less, 170 PP subjects per arm were necessary to have 90% power to show clinical noninferiority of AR-13324 to timolol in mean IOP.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Clinical noninferiority was to be concluded if the upper limit of the 95% CIs around the difference (AR-13324 - timolol) was within 1.5 mmHg at all time points and was within 1.0 mmHg at a majority of the time points.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Calculated p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Statistical analysis applies at all 3 timepoints on Day 15, Day 43, and Day 90</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Exposure</title>
        <description>Exposure to study medication in days for all treatment groups.</description>
        <time_frame>3 months</time_frame>
        <population>Safety Population: all randomized subjects who received at least 1 dose of study medication. The safety population summarizes subjects as treated for purpose of analysis. Three (3) subjects received incorrect study medication from that to which they were randomized, shown in the Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</title>
            <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate Ophthalmic Solution 0.5% BID</title>
            <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Exposure</title>
          <description>Exposure to study medication in days for all treatment groups.</description>
          <population>Safety Population: all randomized subjects who received at least 1 dose of study medication. The safety population summarizes subjects as treated for purpose of analysis. Three (3) subjects received incorrect study medication from that to which they were randomized, shown in the Participant Flow.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" spread="21.44"/>
                    <measurement group_id="O2" value="87.4" spread="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the course of the 90-day treatment period.</time_frame>
      <desc>The Safety Population included all randomized subjects who received at least 1 dose of study medication and was used to summarize safety variables. Three (3) subjects received incorrect study medication from that to which they were randomized, shown in the Participant Flow.</desc>
      <group_list>
        <group group_id="E1">
          <title>AR-13324 Ophthalmic Solution 0.02% &amp; Placebo</title>
          <description>1 drop AR-13324 in the evening (PM) &amp; 1 drop placebo in the morning (AM) in both eyes (OU)</description>
        </group>
        <group group_id="E2">
          <title>Timolol Maleate Ophthalmic Solution 0.5% BID</title>
          <description>1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Exacerbation of Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Left Upper Extremity Numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Stroke (CVA)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Conjunctival Haemmorrhage</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Cornea Verticillata</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Erythema of Eyelid</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="208"/>
              </event>
              <event>
                <sub_title>Instillation Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vital Dye Staining Cornea Present</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="208"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Ramirez-Davis, Director Clinical Project Management</name_or_title>
      <organization>Aerie Pharmaceuticals, Inc.</organization>
      <phone>908-947-3543</phone>
      <email>nramirez@aeriepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

